Clinical trials: Overall Response Rate
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese…
- Trial name
- NCT05670106
- Testing
- [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11
- Where
- 17 sites in China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Idiopathic Thrombocytopenic Purpura
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
This single arm study will evaluate the efficacy and safety of MabThera monotherapy in patients with refractory, relapsing or chronic idiopathic thrombocytopenic purpura (ITP).
- Trial name
- NCT00475423
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 12 sites in Australia
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Gonorrhea
Response Rate to Ceftriaxone 1g IM in Gonorrhoea : a French Retrospective Monocentric Study
Sexual health centers (CeGIDD, in France) manage the majority of STI in France, especially gonorrhea. Patients wanting STI screening can consult either they are symptomatic or not.
- Trial name
- GONOCEF (NCT04902560)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Montpellier
Colorectal Cancer (CRC)
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
This is a prospective, open-label, randomized, parallel-group phase II trial evaluating the efficacy and safety of a low-dose radiotherapy sensitization strategy combined with a PD-1 antibody (pucotenlimab) and CAPEOX as…
- Trial name
- NCT07448142
- Testing
- Low-dose radiotherapy, Pucotenlimab, CAPEOX/XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of the ECF regimen (epirubicin, cisplatin and FU) combined with endostar-- a inhibitor of angiogenesis, in patients with advanced or metastatic gastric cancer…
- Trial name
- NCT00595972
- Testing
- ECF-endostar
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Gastric Cancer
Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC
The purpose of this study is to evaluate the efficacy and tolerability of the combination of epirubicin, oxaliplatin and 5-day continuous infusional 5-fluorouracil (EOF5 regimen) in patients with unresectable advanced or…
- Trial name
- NCT00767377
- Testing
- EOF5
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Fudan University
Multiple Myeloma
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib
The purpose of this study is to evaluate the overall response rate of Trametinib when administered orally to patients with relapsed or refractory multiple myeloma
- Trial name
- NCT02140840
- Testing
- Trametinib
- Where
- United States
- Sponsor
- University of Arkansas
Sarcoma
Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
This is a randomized open label study, with 2 arms treatments conducted in patients with metastatic or unresectable advanced sarcoma of rare subtype; previously treated by anthracycline-based regimen except for whom standard…
- Trial name
- RAR-Immune (NCT04741438)
- Testing
- Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
- Where
- 13 sites in France
- Volunteers
- 96 people
- Sponsor
- Centre Leon Berard
Advanced Malignancy, Advanced Solid Cancers
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Cancers, Metastatic Solid Tumors
- Trial name
- NCT07238075
- Testing
- ADCX-020
- Where
- 9 sites in Australia, Spain
- Volunteers
- 290 people
- Sponsor
- Adcytherix SAS
Colorectal Neoplasms
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
The purpose of this study is to evaluate the Progression-Free Survival (PFS) time of Sorafenib in combination with FOLFIRI regimen used as in the second front treatment in patients with advanced CRC after failure of oxaliplatin…
- Trial name
- NCT00839111
- Testing
- sorafenib, FOLFIRI
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.
The present project is a multicenter, phase II trial which aims at evaluating if the administration of azacytidine (Vidaza®) combined to donor lymphocyte infusion (DLI) could improve the response rate to DLI in the population of…
- Trial name
- NCT02017457
- Testing
- Donor lymphocyte infusion, Azacytidine
- Where
- 12 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Carlos Graux, MD, PhD
Tumor Response Rate, Overall Survival
TILA-TACE in Treatment of Hepatocellular Carcinoma
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate.
- Trial name
- NCT03910140
- Testing
- TILA-TACE treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Graft Vs Host Disease
A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease
This is an academic open-label, phase II randomized study in patients with steroid resistant severe acute Graft versus host disease (GvHD) who have had allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT05132166
- Testing
- Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib., Decidual Stromal Cells
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
T-LGL Leukemia, NK-LGL Leukemia
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
There is currently no standard first-line treatment for LGLL. The investigators used the TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2020, enrolling a total of 54 patients and achieving an overall…
- Trial name
- NCT06530576
- Testing
- Thalidomide and methotrexate
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Progress-free Survival, Overall Response Rate
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China.
- Conditions
- Progress-free Survival, Overall Response Rate, Adverse Events
- Trial name
- HOPES (NCT01291667)
- Volunteers
- 330 people
- Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd.
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease…
- Conditions
- Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
- Trial name
- ATEZOGIST (NCT05152472)
- Testing
- Atezolizumab 1200 mg, Imatinib 400 MG
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Nasopharyngeal Carcinoma
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the clinical efficacy of apatinib mesylate tablets combined with PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma after IMRT with concurrent chemotherapy,including The Overall…
- Trial name
- NCT04350190
- Testing
- Apatinib mesylate tablet, PD-1
- Where
- 5 sites in China
- Volunteers
- 25 people
- Sponsor
- Wei Jiang
Squamous Cell Carcinoma of the Penis
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)
The purpose of this study is to evaluate the efficacy and safety of Cetuximab in metastatic penile carcinoma
- Trial name
- PENILANE (NCT02014831)
- Testing
- Cetuximab, TIP
- Where
- 7 sites in France
- Sponsor
- Centre Leon Berard